Back
24 June 2025
The ITA reports that kurash athlete Malak Hamdy Mostafa has been sanctioned with a two-year period of ineligibility for an Anti-Doping Rule Violation (ADRV) under Article 2.1 and Article 2.2 of the IKA anti-doping rules (IKA ADR).
The athlete provided a sample on 9 July 2023 during an in-competition anti-doping control conducted during the African Championship held in Cairo, Egypt from 7 to 13 July 2023. After analysis by a World Anti-Doping Agency (WADA)-accredited laboratory, the sample returned an adverse analytical finding¹ for furosemide.
Furosemide is prohibited under the WADA Prohibited List as S5. Diuretics and Masking Agents. It is prohibited at all times (in- and out-of-competition) and is classified as a specified substance. Furosemide can be used by athletes to excrete water for rapid weight loss.
The athlete did not challenge her ADRV. Pursuant to Article 8.3.3 of the IKA ADR, the ITA issued a sanctioning decision² imposing the applicable consequences, namely a period of ineligibility of two years from 5 May 2025 until 4 May 2027 and the disqualification of her competitive results from 9 July 2023 onwards.
The decision is subject to appeal before the appeals division of CAS in accordance with article 13.2.3 of the IKA ADR.
The ITA will not comment further on this case.
¹ A report from a WADA-accredited laboratory that, consistent with the International Standard for Laboratories, establishes in a sample the presence of a prohibited substance or its metabolites or markers or evidence of the use of a prohibited method.
² When an athlete does not challenge the assertion of an ADRV and does not request a hearing, anti-doping organisations have the possibility to issue a written decision sanctioning the athlete and imposing the applicable consequences without having to refer the case to a hearing panel. This is provided in articles 8.3.2 and 8.3.3 of the IKA anti-doping rules and article 8.3 of the World Anti-Doping Code.
